Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/26/2025

Ezetimibe's Triglyceride-Lowering Effects

Mechanism and Efficacy

  • The American College of Cardiology recommends ezetimibe as it works by inhibiting the NPC1L1 protein in the small intestine, which reduces cholesterol absorption, with modest effects on triglyceride levels 1, 2

Monitoring and Treatment

  • The American College of Cardiology suggests obtaining a baseline lipid panel before initiating ezetimibe and follow-up lipid panel to assess triglyceride response at 4-6 weeks after initiation 3, 2, 4
  • For patients on combination therapy with statins, monitoring of hepatic transaminases is recommended as clinically indicated, according to the American College of Cardiology 3

Comparative Efficacy

  • Ezetimibe's triglyceride-lowering effect (10-15%) is modest compared to fibrates (30-50% reduction), as reported by the American Heart Association 5
  • Ezetimibe's triglyceride-lowering effect is also modest compared to omega-3 fatty acids (20-45% reduction) and niacin (up to 50% reduction), according to the American College of Cardiology 3, 6

Clinical Considerations

  • The American College of Cardiology states that ezetimibe is generally well-tolerated with minimal side effects 2
  • For patients with severely elevated triglycerides, the American College of Cardiology recommends fibrates or omega-3 fatty acids as first-line therapy, rather than ezetimibe 3
  • The American College of Cardiology suggests that ezetimibe can be an appropriate addition to statin therapy for patients with mixed dyslipidemia (elevated LDL-C and modestly elevated triglycerides) 1, 2

Additional Considerations

  • The American College of Cardiology notes that the primary indication for ezetimibe is LDL-C reduction, not triglyceride lowering 1, 2
  • The American College of Cardiology recommends avoiding bile acid sequestrants in patients with triglycerides >300 mg/dL, as they may worsen hypertriglyceridemia 3, 4
  • The American College of Cardiology states that patients with diabetes may experience greater triglyceride-lowering benefits from ezetimibe compared to non-diabetic patients 7
  • The American College of Cardiology suggests that lifestyle modifications, including dietary changes, weight loss, and exercise, should be implemented alongside pharmacotherapy for optimal triglyceride reduction 8

REFERENCES